ENZN
Undervalued by 443.3% based on the discounted cash flow analysis.
Market cap | $6.01 Million |
---|---|
Enterprise Value | $-38,623,617.00 |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.01 |
Beta | 0.24 |
Outstanding Shares | 74,215,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -91.08 |
---|---|
PEG | 34.53 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | -1485.52 |
Enterprise Value to EBIT | -254.1 |
Enterprise Value to Net Income | 585 |
Total Debt to Enterprise | -0.01 |
Debt to Equity | 0.17 |
No data
No data
Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the ...